The single character that determines whether your year on tirzepatide costs $300 or $7,500 is the diagnosis code your doctor enters in the EHR before sending the prescription. E11.9 (type 2 diabetes without complications) routes you to Mounjaro through a covered diabetes pathway. E66.01 (morbid obesity) routes you to Zepbound through an obesity pathway most plans do not cover. The drug is the same. The pen is the same. The dose is the same. The diagnosis decides everything.
This article explains how the billing-code system actually works, why pharmacies and PBMs treat the same molecule so differently based on labeled indication, and what to do if you have both diagnoses (which a lot of patients do).
How prescription billing actually works
When a prescription is sent from a doctor's office to a pharmacy, three pieces of information travel together: the drug, the dose, and the indication (typically expressed as one or more ICD-10 diagnosis codes). At the pharmacy, when the prescription is processed through insurance, the pharmacy benefit manager (PBM) checks the diagnosis code against the plan's formulary rules. The PBM is essentially asking: "Does this plan cover this drug for this condition?"
For most prescriptions this is a routine check that completes in milliseconds. For tirzepatide, it is the gate that determines whether you pay $25 or $1,069.
The relevant ICD-10 codes for the GLP-1 conversation:
| Code | Diagnosis | Coverage status (typical) |
|---|---|---|
| E11.9 | Type 2 diabetes mellitus without complications | Universal coverage |
| E11.65 | Type 2 diabetes with hyperglycemia | Universal coverage |
| E11.40-E11.49 | Type 2 diabetes with neurological complications | Universal coverage |
| E66.01 | Morbid (severe) obesity due to excess calories | ~50% coverage |
| E66.9 | Obesity, unspecified | ~30-40% coverage |
| Z68.4x | BMI 40+ (used as supporting code) | Supporting only |
| R73.03 | Prediabetes | Rarely covered for GLP-1 |
The diabetes path: Mounjaro + E11.9
When a prescription for Mounjaro arrives at the pharmacy with E11.9 attached, the system does the following:
- Verify the patient has prescription drug coverage with the plan.
- Check whether Mounjaro is on the plan's formulary. (For commercial and Medicare Part D plans in 2026, the answer is almost always yes.)
- Check the formulary tier and apply the patient's copay structure.
- Apply any active manufacturer savings card on top of the insurance benefit.
- Quote the patient their out-of-pocket: typically $25 with savings card, $35-$150 without.
The diabetes path is well-trodden. It is what insurance was designed to cover. There are still occasional prior authorization requirements (some plans want documentation of prior metformin or other oral therapy), but for the vast majority of diabetes patients, this path completes smoothly with low out-of-pocket cost.
The obesity path: Zepbound + E66.01
When a prescription for Zepbound arrives at the pharmacy with E66.01 attached, the system runs a different gauntlet:
- Verify the patient has prescription drug coverage. (Yes.)
- Check whether the plan covers weight-loss medications at all. Roughly 50-60% of commercial plans in 2026 either exclude weight-loss medications entirely or require specific riders. Medicare Part D is statutorily prohibited from covering drugs used for weight loss. Most state Medicaid programs do not cover them.
- If the plan covers weight-loss meds: verify Zepbound specifically is on formulary, check for prior authorization (typically required: documented BMI, prior diet/exercise attempts, sometimes prior failed pharmacotherapy).
- If prior auth is approved: apply tier copay. Patient typically pays $25-$150 with savings card.
- If the plan does not cover weight-loss meds, or PA is denied: the patient is quoted the cash price of approximately $1,086 a month, often with no warning that this was about to happen.
The volume of patients who go through this path expecting a $25 fill and get hit with a $1,086 quote is one of the most common — and most preventable — bad experiences in the entire GLP-1 market.
Before your doctor sends a Zepbound prescription, call your insurance member services line and ask three specific questions. (1) Does my plan cover weight-loss medications? (2) Is Zepbound on my formulary? (3) What are the prior authorization requirements? Get the answer in writing if possible. If the answer to any of these is "no," you know before you walk into the pharmacy that you need a different route.
If you have both diagnoses (which is more common than you think)
The 2017-2020 NHANES data shows that approximately 40% of US adults with type 2 diabetes also meet BMI criteria for obesity (BMI ≥ 30). That is millions of patients who legitimately carry both diagnoses. For those patients, the choice of which billing pathway to use is meaningful — and largely up to the prescribing physician's clinical judgment plus the patient's coverage situation.
The general decision logic that most prescribers follow in 2026:
| Patient situation | Likely best route | Why |
|---|---|---|
| T2D + obesity, with insurance covering both | Mounjaro on E11.9 | Diabetes pathway is more reliable, copays equivalent |
| T2D + obesity, insurance covers diabetes only | Mounjaro on E11.9 | Only viable insured route |
| T2D + obesity, insurance covers obesity only (rare) | Zepbound on E66.01 | Only viable insured route |
| Obesity only, insurance covers it | Zepbound on E66.01 | Labeled use, normal pathway |
| Obesity only, insurance does not cover it | LillyDirect Zepbound vials or compounded | Bypass insurance entirely |
This is a clinical decision your prescriber makes in collaboration with you. The honest framing is that for a patient with both diagnoses, prescribing Mounjaro for the diabetes indication is straightforward and well-supported clinically. It is not "gaming" the system; type 2 diabetes is a real diagnosis with a labeled drug, and you genuinely have the condition.
What happens if your doctor picks the wrong path
Scenario 1: Doctor writes Mounjaro for an obesity-only patient. This is off-label prescribing of a diabetes drug. It is technically legal — physicians can prescribe FDA-approved drugs off-label — but pharmacies and PBMs increasingly catch these prescriptions and reject them. The pharmacy may call the prescriber to clarify the diagnosis. If the patient does not actually have diabetes and there is no diabetes diagnosis in the chart to support the prescription, this can create real problems for both patient (denied coverage, unexpected cost) and prescriber (chart documentation issues, potential audit exposure).
Scenario 2: Doctor writes Zepbound for a diabetes-only patient. This is also off-label. The patient does not have an obesity diagnosis, the prescription will likely be rejected by PA, and the patient will be quoted the cash price. Worse, the patient gives up coverage they could have had under Mounjaro for the same molecule.
Scenario 3: Doctor writes the right drug but uses the wrong supporting code. This is the most common mistake — a Zepbound prescription for an obese patient that does not include the BMI z-code (Z68.4x) as supporting documentation, leading to a prior auth denial that gets reversed once the doctor's office submits the missing code. Frustrating but recoverable.
If you do not have type 2 diabetes, do not ask your doctor to write Mounjaro for you with a fake diabetes code. This is insurance fraud. It can lead to retroactive coverage denial, repayment demands, and serious problems for your physician's license. The legitimate routes for cash-pay or insurance-denied obesity patients — LillyDirect, compounded telehealth, manufacturer assistance — are real and accessible. There is no need to falsify a diagnosis.
How to make sure you're on the right path
Before you leave your prescriber's office with a tirzepatide prescription, run through this five-question checklist:
1. Which drug did you prescribe — Mounjaro or Zepbound? Be sure you know which one is on the prescription. They are not interchangeable in the pharmacy system.
2. What diagnosis code did you attach? Specifically ask for the ICD-10 code. If E11.x, you are on the diabetes path. If E66.x, you are on the obesity path. If R73.03 (prediabetes), insurance is unlikely to cover either drug.
3. Did you submit a prior authorization? For Zepbound, PA is almost always required. Confirm whether the office submitted it and how to follow up on the decision.
4. What pharmacy did you send the prescription to? If you have a preferred pharmacy with better cash pricing, make sure that is the one receiving the prescription.
5. What's my Plan B if insurance denies it? Have this conversation upfront. The doctor can usually have a backup plan ready — typically a referral to LillyDirect, NovoCare Direct, or an in-network telehealth route — so that a denial does not turn into a treatment delay.
The bottom line
Mounjaro and Zepbound are the same drug, but the US insurance system treats them as completely different products because they carry different FDA-labeled indications. The diagnosis code on your prescription decides which pathway you travel through, and the pathway determines whether your year on tirzepatide costs you $300 or $7,500.
If you have type 2 diabetes, the diabetes pathway via Mounjaro is the clean route. If you have obesity without diabetes, you need to verify your insurance coverage before assuming the obesity pathway via Zepbound will work — because for a sizable portion of US patients, it will not. And if it does not, the brand-name LillyDirect route and the compounded telehealth route both bypass the insurance maze entirely at very different price points.
For the year-long cost projection across all four scenarios, see Zepbound vs Mounjaro Cost Comparison 2026. For the rebate-program details that determine your in-pathway cost, see The 2026 GLP-1 Rebate Database.